Free Trial

PMV Pharmaceuticals Q3 2023 Earnings Report

PMV Pharmaceuticals logo
$1.42 -0.02 (-1.39%)
As of 01/31/2025 04:00 PM Eastern

PMV Pharmaceuticals EPS Results

Actual EPS
-$0.34
Consensus EPS
-$0.45
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

PMV Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

PMV Pharmaceuticals Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

PMV Pharmaceuticals Earnings Headlines

PMV Pharmaceuticals files $200M mixed securities shelf
Unveiling 7 High-Potential Stocks for 2025
Welcome to 2025—a year brimming with exceptional investment possibilities! Our comprehensive guide, "7 Stocks Set to Soar," has been carefully curated to help you enhance your portfolio this year. Stay Ahead with Cutting-Edge Trends This year, advancements in artificial intelligence are driving transformative changes across various sectors. From AI-powered healthcare innovations to intelligent automation in manufacturing, these technological breakthroughs are creating fertile ground for select companies to thrive. Our guide delves into how these trends are shaping the future and spotlighting the stocks positioned to capitalize on them.
PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
PMV Pharmaceuticals Reports Third Quarter 2024 Financial Results
Oppenheimer Sticks to Its Hold Rating for PMV Pharmaceuticals (PMVP)
See More PMV Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PMV Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PMV Pharmaceuticals and other key companies, straight to your email.

About PMV Pharmaceuticals

PMV Pharmaceuticals (NASDAQ:PMVP), a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.

View PMV Pharmaceuticals Profile

More Earnings Resources from MarketBeat